LEO Pharma to Present 17 Scientific Abstracts at AAD 2026

Highlighting Real-World Evidence, Long-Term Outcomes and Patient Experience Across Multiple Dermatological Conditions

Mar. 23, 2026 at 3:51am

Got story updates? Submit your updates here. ›

LEO Pharma, a global leader in medical dermatology, announced it will present 17 scientific posters at the 2026 American Academy of Dermatology (AAD) Annual Meeting, highlighting new real-world and clinical data across its medical dermatology portfolio and pipeline for inflammatory skin diseases.

Why it matters

The data being presented by LEO Pharma at AAD 2026 reflects continued advancements in the understanding and management of chronic dermatologic diseases and underscores the company's ambition to help address critical treatment gaps for patients.

The details

Key data to be presented by LEO Pharma includes 12-month real-world data from the TRACE study evaluating the safety and effectiveness of ADBRY (tralokinumab) among patients with atopic dermatitis, data evaluating outcomes with ANZUPGO (delgocitinib) cream 20 mg/g in adults with moderate-to-severe chronic hand eczema, and long-term data from the EFFISAYIL program evaluating SPEVIGO (spesolimab) for the treatment of GPP flares.

  • The 2026 AAD Annual Meeting will take place from March 27-31 in Denver, Colorado.

The players

LEO Pharma A/S

A global leader in medical dermatology that is presenting the 17 scientific abstracts at the 2026 AAD Annual Meeting.

ADBRY (tralokinumab)

A high-affinity fully human monoclonal antibody developed to bind to and inhibit the interleukin (IL)-13 cytokine, which plays a role in the immune and inflammatory processes underlying atopic dermatitis signs and symptoms.

ANZUPGO (delgocitinib) cream

A topical pan-Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe chronic hand eczema in adults.

SPEVIGO (spesolimab)

A humanized, selective antibody that specifically blocks the activation of the IL-36R, a signaling pathway within the immune system shown to be involved in the pathogenesis of several autoinflammatory diseases, including generalized pustular psoriasis (GPP).

Got photos? Submit your photos here. ›

What they’re saying

“We're proud to present LEO Pharma's largest body of research to date at the AAD Annual Meeting, highlighting new real-world and clinical insights across Atopic Dermatitis, Generalized Pustular Psoriasis and Chronic Hand Eczema.”

— Sophie Lamle, EVP, Development at LEO Pharma

The takeaway

The data being presented by LEO Pharma at AAD 2026 demonstrates the company's continued commitment to advancing the understanding and management of chronic dermatologic diseases, with the goal of addressing critical treatment gaps and improving outcomes for patients.